What does PRODIVET PHARMACEUTICALS do?

PRODIVET PHARMACEUTICALS is a wholesaler in Raeren. Public Limited, started on 18 January 1983, 1 establishment.

What is the address of PRODIVET PHARMACEUTICALS?

The registered office of PRODIVET PHARMACEUTICALS is located at Hagbenden 39C, 4731 Raeren.

Is PRODIVET PHARMACEUTICALS still active?

Yes. According to the CBE (29 October 2026) PRODIVET PHARMACEUTICALS is active, legal situation “Normale toestand”, started on 18 January 1983.

Is PRODIVET PHARMACEUTICALS registered on Peppol?

Yes, PRODIVET PHARMACEUTICALS is registered on the Peppol network with ID 0208:0423519816.

What is the enterprise number of PRODIVET PHARMACEUTICALS?

The enterprise number of PRODIVET PHARMACEUTICALS is BE0423519816.

When was PRODIVET PHARMACEUTICALS founded?

PRODIVET PHARMACEUTICALS was founded on 18 January 1983.

Who are the directors of PRODIVET PHARMACEUTICALS?

According to the 2025 annual accounts, the directors of PRODIVET PHARMACEUTICALS are: Yves OSSEMANN, Dorothea HICK-ROX, HEDO AG.

Is PRODIVET PHARMACEUTICALS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 January 1983; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PRODIVET PHARMACEUTICALS make in 2025?

PRODIVET PHARMACEUTICALS posted a profit after taxes of € 101,374 in financial year 2025.

What is the revenue of PRODIVET PHARMACEUTICALS?

As a small company, PRODIVET PHARMACEUTICALS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 861,860.

How much does an employee at PRODIVET PHARMACEUTICALS earn?

The average wage cost per full-time employee at PRODIVET PHARMACEUTICALS was € 66,700 in 2025: staff costs of € 573,683 for 8.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PRODIVET PHARMACEUTICALS have?

According to the 2025 annual accounts, PRODIVET PHARMACEUTICALS has 8.6 full-time equivalents (FTE).

PRODIVET PHARMACEUTICALS (Public Limited) - Raeren

Dossier PRODIVET PHARMACEUTICALS, printed on 29 October 2026 from databakkes.be/en/0423519816/prodivet-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PRODIVET PHARMACEUTICALS from Raeren, company number BE0423519816, closed financial year 2025 with a result of € 101,374 after tax. For that financial year PRODIVET PHARMACEUTICALS recorded a gross margin of € 861,860 and equity of € 2.8 million. Compared with financial year 2024, the result moved from € 251,066 to € 101,374. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.

What it is worth Growing

€ 2.8 million

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 101,374

▼ 60% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.4 million

▲ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2.7 million.

People and assets in 2025

Full-time equivalents

8.6

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 573,683

▼ 1% vs 2024

€ 66,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 128,214

▼ 27% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 127,472

▲ 91% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 168,601

▼ 6% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,030,794 Gross margin 2022: € 1,030,794 First fiscal year in the series	€ 959,782 Gross margin 2023: € 959,782 ▼ 7% vs 2022 (€ 1,030,794) Unfavourable step	€ 1,081,902 Gross margin 2024: € 1,081,902 ▲ 13% vs 2023 (€ 959,782) Favourable step	€ 861,860 Gross margin 2025: € 861,860 ▼ 20% vs 2024 (€ 1,081,902) Unfavourable step	▼ 20%
Profit after taxes	€ 426,576 Profit after taxes 2022: € 426,576 First fiscal year in the series	€ 146,379 Profit after taxes 2023: € 146,379 ▼ 66% vs 2022 (€ 426,576) Unfavourable step	€ 251,066 Profit after taxes 2024: € 251,066 ▲ 72% vs 2023 (€ 146,379) Favourable step	€ 101,374 Profit after taxes 2025: € 101,374 ▼ 60% vs 2024 (€ 251,066) Unfavourable step	▼ 60%
Equity	€ 2,315,271 Equity 2022: € 2,315,271 First fiscal year in the series	€ 2,461,650 Equity 2023: € 2,461,650 ▲ 6% vs 2022 (€ 2,315,271) Favourable step	€ 2,712,717 Equity 2024: € 2,712,717 ▲ 10% vs 2023 (€ 2,461,650) Favourable step	€ 2,814,090 Equity 2025: € 2,814,090 ▲ 4% vs 2024 (€ 2,712,717) Favourable step	▲ 4%
Total debts	€ 845,992 Total debts 2022: € 845,992 First fiscal year in the series	€ 501,769 Total debts 2023: € 501,769 ▼ 41% vs 2022 (€ 845,992) Favourable step	€ 447,532 Total debts 2024: € 447,532 ▼ 11% vs 2023 (€ 501,769) Favourable step	€ 505,592 Total debts 2025: € 505,592 ▲ 13% vs 2024 (€ 447,532) Unfavourable step	▲ 13%
Cash	€ 1,666,000 Cash 2022: € 1,666,000 First fiscal year in the series	€ 1,129,712 Cash 2023: € 1,129,712 ▼ 32% vs 2022 (€ 1,666,000) Unfavourable step	€ 1,241,971 Cash 2024: € 1,241,971 ▲ 10% vs 2023 (€ 1,129,712) Favourable step	€ 1,389,359 Cash 2025: € 1,389,359 ▲ 12% vs 2024 (€ 1,241,971) Favourable step	▲ 12%
Land & buildings	€ 98,987 Land & buildings 2022: € 98,987 First fiscal year in the series	€ 104,919 Land & buildings 2023: € 104,919 ▲ 6% vs 2022 (€ 98,987) Unchanged	€ 104,796 Land & buildings 2024: € 104,796 Unchanged (€ 104,919) Unchanged	€ 99,378 Land & buildings 2025: € 99,378 ▼ 5% vs 2024 (€ 104,796) Unchanged	▼ 5%
Retained profit	€ 2,213,751 Retained profit 2022: € 2,213,751 First fiscal year in the series	€ 2,360,130 Retained profit 2023: € 2,360,130 ▲ 7% vs 2022 (€ 2,213,751) Favourable step	€ 2,611,197 Retained profit 2024: € 2,611,197 ▲ 11% vs 2023 (€ 2,360,130) Favourable step	€ 2,712,570 Retained profit 2025: € 2,712,570 ▲ 4% vs 2024 (€ 2,611,197) Favourable step	▲ 4%
Dividend	€ 150,000 Dividend 2022: € 150,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 150,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 3,161,263 Balance sheet total 2022: € 3,161,263 First fiscal year in the series	€ 2,963,419 Balance sheet total 2023: € 2,963,419 ▼ 6% vs 2022 (€ 3,161,263) Unchanged	€ 3,160,249 Balance sheet total 2024: € 3,160,249 ▲ 7% vs 2023 (€ 2,963,419) Unchanged	€ 3,319,683 Balance sheet total 2025: € 3,319,683 ▲ 5% vs 2024 (€ 3,160,249) Unchanged	▲ 5%
Employees (FTE)	9.1 Employees (FTE) 2022: 9.1 First fiscal year in the series	9.5 Employees (FTE) 2023: 9.5 ▲ 0.4 vs 2022 (9.1) Unchanged	8.6 Employees (FTE) 2024: 8.6 ▼ 0.9 vs 2023 (9.5) Unchanged	8.6 Employees (FTE) 2025: 8.6 Unchanged (8.6) Unchanged

Key figures of PRODIVET PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PRODIVET PHARMACEUTICALS?

What happened at PRODIVET PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Yves OSSEMANN stepped down as director. NBB
2029 Dorothea HICK-ROX stepped down as director. NBB
2029 HEDO AG stepped down as director. NBB
May 29, 2026 New annual accounts for financial year 2025: profit of € 101,374 (▼ 60% vs 2024). Source: NBB ↗
2023 Yves OSSEMANN became a director. NBB
2023 Dorothea HICK-ROX became a director. NBB
2023 HEDO AG became a director. NBB
Jan 18, 1983 New establishment in Raeren. KBO

In short

From € 426,576 profit in 2022 to € 101,374 profit in 2025.

Paid € 336,419 in corporate taxes since 2022.

Best year ever: 2022, with € 426,576 profit.

On average € 100,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Yves OSSEMANN

Managing director

Also active at: HEDO, ESCO

since 2023 · until 2029

Dorothea HICK-ROX

Director

Also active at: HEDO, ESCO

since 2023 · until 2029

HEDO AG

Managing director · represented by Herbert OSSEMANN

Also active at: ESCO

since 2023 · until 2029

Establishments

Establishment units

Physical locations of this company

Registered office

Hagbenden 39C

4731 Raeren

2.035.089.395

Hagbenden 39 box C

4731 Raeren

Active since 18 January 1983

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0423.519.816

VAT number

BE 0423.519.816

Registered office

Hagbenden 39C, 4731 Raeren

Names & denominations

PRODIVET PHARMACEUTICALS

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

18 January 1983

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Detailhandel in farmaceutische producten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Apothekers

Detailhandel in medische en orthopedische artikelen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

PRODIVET PHARMACEUTICALS

Financials

What happened to PRODIVET PHARMACEUTICALS?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions